Target Price | $448.29 |
Price | $436.11 |
Potential |
2.79%
register free of charge
|
Number of Estimates | 18 |
18 Analysts have issued a price target Madrigal Pharmaceuticals, Inc. 2026 .
The average Madrigal Pharmaceuticals, Inc. target price is $448.29.
This is
2.79%
register free of charge
$595.35
36.51%
register free of charge
$268.66
38.40%
register free of charge
|
|
A rating was issued by 23 analysts: 20 Analysts recommend Madrigal Pharmaceuticals, Inc. to buy, 2 to hold and 1 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Madrigal Pharmaceuticals, Inc. stock has an average upside potential 2026 of
2.79%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 180.13 | 890.07 |
394.13% | ||
EBITDA Margin | -275.79% | -41.59% |
84.92% | ||
Net Margin | -258.64% | -26.63% |
89.70% |
17 Analysts have issued a sales forecast Madrigal Pharmaceuticals, Inc. 2025 . The average Madrigal Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
6 Analysts have issued an Madrigal Pharmaceuticals, Inc. EBITDA forecast 2025. The average Madrigal Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
19 Madrigal Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Madrigal Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -21.90 | -10.67 |
9.55% | 51.28% | |
P/E | negative | |
EV/Sales | 10.16 |
19 Analysts have issued a Madrigal Pharmaceuticals, Inc. forecast for earnings per share. The average Madrigal Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Madrigal Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
TD Cowen |
Locked
➜
Locked
|
Locked | Aug 26 2025 |
JMP Securities |
Locked
➜
Locked
|
Locked | Aug 20 2025 |
UBS |
Locked
➜
Locked
|
Locked | Aug 12 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | Aug 06 2025 |
B. Riley Securities |
Locked
➜
Locked
|
Locked | May 02 2025 |
UBS |
Locked
➜
Locked
|
Locked | May 02 2025 |
Canaccord Genuity |
Locked
➜
Locked
|
Locked | May 02 2025 |
Analyst Rating | Date |
---|---|
Locked
TD Cowen:
Locked
➜
Locked
|
Aug 26 2025 |
Locked
JMP Securities:
Locked
➜
Locked
|
Aug 20 2025 |
Locked
UBS:
Locked
➜
Locked
|
Aug 12 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Aug 06 2025 |
Locked
B. Riley Securities:
Locked
➜
Locked
|
May 02 2025 |
Locked
UBS:
Locked
➜
Locked
|
May 02 2025 |
Locked
Canaccord Genuity:
Locked
➜
Locked
|
May 02 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.